Another study investigated the combination of anti-PD-1 with an adenovirus engineered to deliver tumor necrosis factor-alpha (TNF-α) and IL-2 in a mouse model of NSCLC: a reduction in cancer growth and an increased number of cytotoxic TILs were noticed, highlighting the potential of this approach [164]. The gene discussed is TNF; the disease is cancer.